Abstract
Introduction: Rheumatic heart disease (RHD) remain significant causes of cardiovascular disease and mortality in children particularly in the developing countries. This study aims to evaluate ASO titer in rheumatic heart disease patients who are on secondary prophylaxis. Methods: A cross sectional study method was employed to collect blood sample from RHD patients (children) who are on secondary prophylaxis at pediatric clinic of Debre Brehan referral hospital. The blood sample was collected, transported and processed based on standard operating procedures (SOPs) for ASO titer determination. And finally, the data was analyzed using SPSS version 21and P-value less than or equal to 0.05 was taken as statistically significant. Result: A total of 123 children on secondary prophylaxis for RHD; in the age range of 5-15 years are included. Of these, 65 (52.8) were male and 58 (47.2%) were female; 69 (56.1%) were from rural and 54 (43.9%) were from urban area. The highest frequency of participant 52 (42.3%) were in the age group of 9-12 years. Among participants 74 (60.2%) had history of pharyngitis. The result of ASO titer shows 78 (63.4%) were positive in antistreptolysin O slide agglutination test; 30 (24.4%) patients have 400IU/ml ASO titer, 19 (15.4%) patients have 600 IU/ml ASO titer, 17 (13.8%) patients have ASO titer 800 IU/ml and 12 (9.8%) patients have ASO titer >1000 IU/ml. Conclusion: This study suggest that in most children admitted with RHD have recent streptococcal infection as evident by raised ASO titer.
Highlights
Rheumatic heart disease (RHD) remain significant causes of cardiovascular disease and mortality in children in the developing countries
Patients with RHD are at risk of recurrent attacks of rheumatic fever resulting in ongoing inflammation and fibrosis with consequent valvular damage [2, 3]
A total of 123 children on secondary prophylaxis for RHD; in the age range of 5-15 years are included in this study
Summary
Rheumatic heart disease (RHD) remain significant causes of cardiovascular disease and mortality in children in the developing countries. Its incidence is decreasing in industrialized countries, RHD remains a major challenge in the rest of the world. It is a leading cause of morbidity and mortality among young adults in the developing world, accounting for at least 345,000 deaths annually [4, 5]. This study aims to evaluate ASO titers in rheumatic heart disease patients who are on secondary prophylaxis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
